Clinical Research in Saudi Arabia: Regulatory and Operational Considerations
Saudi Arabia is becoming an increasingly important market for clinical research in the Middle East. Investment in healthcare innovation, an evolving regulatory environment, large specialist healthcare institutions and growing experience with complex studies are strengthening the Kingdom's research ecosystem.
This momentum is measurable. The Saudi Food and Drug Authority (SFDA) reported an 83% increase in clinical-trial applications involving advanced therapies and biotechnology products in 2025, alongside a 39% increase in early-stage clinical trials. Approximately 2,700 patients accessed innovative or advanced treatments through clinical-trial participation. Saudi Food and Drug Authority
For pharmaceutical, biotechnology and research organizations considering Saudi Arabia, however, successful study delivery depends on more than identifying experienced investigators. Regulatory strategy, ethics approvals, site selection, contracting, data governance and operational planning need to be considered together from the outset.
Understanding the Saudi regulatory pathway
The Saudi Food and Drug Authority (SFDA) has a central role in the evaluation, registration and oversight of clinical trials conducted in the Kingdom. Its responsibilities include reviewing clinical-trial files, establishing requirements, maintaining clinical-trial information and conducting GCP inspections of sites and research organizations. Saudi Food and Drug Authority
Importantly, requirements vary according to the type and phase of research. Sponsors should distinguish between interventional drug trials, Phase IV studies, medical-device investigations and other forms of clinical or observational research rather than assuming that one regulatory pathway applies to every study.
The SFDA published an updated Regulation and Requirements for Conducting Clinical Trials on Drug in July 2026, making review of the current requirements particularly important when planning new studies. Saudi Food and Drug Authority
For drug clinical trials, the regulatory framework includes registration through the Saudi Clinical Trials Registry (SCTR). Registration itself should not be confused with regulatory approval. SFDA requirements also address matters such as IRB approval, informed consent, protocols, investigator documentation, GCP training, clinical trial agreements, monitoring arrangements and CRO authorization where applicable. Saudi Food and Drug Authority
For medical-device clinical studies, SFDA states that prior approval is required in accordance with its applicable medical-device clinical-study requirements and ISO 14155. Saudi Food and Drug Authority
Ethics and IRB approval remain fundamental
Clinical research must also operate within Saudi Arabia's ethical research framework. Health research is subject to the Kingdom's requirements governing research ethics on living creatures, with local Institutional Review Boards (IRBs) forming an important component of research authorization and participant protection. Saudi Health Council
From an operational perspective, this means sponsors and CROs should assess site-specific IRB pathways early.
Documentation requirements, committee schedules, institutional processes and contracting arrangements can affect start-up timelines. Arabic-language requirements should also be identified early, particularly for participant-facing documentation.
Rather than treating regulatory, IRB and site start-up as completely separate workstreams, an integrated start-up strategy can help identify dependencies before they become study delays.
Data protection needs to be built into study design
Data governance has become another critical consideration.
Saudi Arabia's Personal Data Protection Law (PDPL) applies to processing personal data relating to individuals in the Kingdom, including certain processing undertaken by entities outside Saudi Arabia. Saudi requirements emphasize data minimization and organizational, administrative and technical safeguards for personal data. SDAIA
Health data receives additional protection. Applicable requirements address matters including restricted access, defined responsibilities, documentation of health-data processing and obligations between controllers and processors. Data Governance Platform
For clinical research, these considerations can affect:
EDC and technology selection
database architecture and hosting
data access and user permissions
transfers and sharing of research data
sponsor, CRO and vendor responsibilities
informed-consent language
data-management and sharing plans
retention and destruction arrangements
These questions are best resolved before database build and site activation, rather than after participant data have already been collected.
Site feasibility needs to go beyond patient numbers
Saudi Arabia includes major tertiary and specialist institutions with substantial clinical expertise. Yet a large theoretical patient population does not necessarily translate into achievable recruitment.
High-quality feasibility should assess the actual protocol-defined population, including prior treatment exposure, diagnostic criteria, disease duration, laboratory availability, competing studies and whether required clinical variables are routinely captured.
Operational feasibility is equally important. Sponsors should assess:
investigator and research-team capacity
availability of trained study coordinators
GCP training and documentation
IRB processes
contracting and budget timelines
pharmacy and laboratory capabilities
source-document accessibility
monitoring arrangements
data and technology requirements
realistic recruitment potential
This is particularly important for complex eligibility criteria and retrospective or real-world studies, where the availability of the required historical data can be just as important as the number of patients treated at the institution.
Contracting and budgeting should start early
Institutional contracting can be a significant component of Saudi study start-up.
Budgets may involve multiple cost categories, including investigator and coordinator activities, institutional overhead, IRB-related costs, pharmacy or laboratory services, administrative fees and archiving. VAT and institutional payment requirements may also need to be considered.
A practical approach is to initiate budget and contract discussions early and in parallel with other start-up activities where permitted, rather than waiting until every other step has been completed.
Clear allocation of responsibilities between the sponsor, CRO, institution and investigator also reduces ambiguity later in the study.
Inspection readiness should begin at activation
Regulatory compliance is not simply a start-up exercise. The SFDA actively conducts GCP inspections of clinical trial sites, CROs and other relevant facilities. In 2025 alone, its Clinical Trials Oversight Division reported 35 GCP inspections. Saudi Food and Drug Authority
The SFDA describes its inspection approach as supporting participant safety, data reliability and compliance with applicable GCP and local regulatory requirements. Saudi Food and Drug Authority
This makes continuous quality oversight important throughout the study lifecycle.
Sponsors and research teams should establish strong processes from the beginning for essential-document management, delegation and training records, protocol compliance, source documentation, safety reporting, monitoring, data quality, deviation management and corrective and preventive actions.
In other words, inspection readiness should be built into study operations rather than introduced shortly before close-out.
The regulatory environment is continuing to evolve
Saudi Arabia's clinical-research environment should not be viewed as static.
The SFDA has been introducing initiatives intended to increase regulatory efficiency and support innovation. In January 2026, the authority reported that its Reliance Pathway for Clinical Trials reduced approval time by 74% compared with the standard pathway. Saudi Food and Drug Authority
Saudi Arabia is also participating in international regulatory harmonization. SFDA materials list ICH E6(R3) Good Clinical Practice among ICH guidance adopted in April 2026. الهيئة العامة للغذاء والدواء
These developments reinforce an important point for sponsors: regulatory planning should be based on current Saudi requirements, not simply on processes used for previous studies in the Kingdom or elsewhere in the Gulf.
From regulatory approval to operational delivery
Saudi Arabia presents substantial opportunities for clinical research, but successful execution requires a locally informed approach.
The strongest study plans connect regulatory strategy, ethics, feasibility, contracting, site operations, data governance, monitoring and quality management from the beginning.
For international sponsors entering Saudi Arabia, local operational knowledge can be particularly valuable—not only for navigating requirements, but also for understanding how those requirements translate into practical execution at individual institutions.
How VI Research can support
VI Research supports clinical research programs across Saudi Arabia and the wider Middle East, providing services across the study lifecycle, including study design and feasibility, regulatory and start-up coordination, site identification and activation, clinical project management, investigator and site management, monitoring, data and document oversight, vendor coordination, quality management and study close-out.
Our approach recognizes that clinical studies differ in design, therapeutic area, evidence requirements and operational complexity. Study delivery should therefore be built around the specific research question, regulatory pathway, sites and patient population—not a one-size-fits-all model.